Saturday 17 October 2026
Export RNXT’s income statement to Excel — free account
RenovoRx, Inc.
RNXT Healthcare Biotechnology
RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024. In the quarter to June 2026, revenue grew 115.4%, EPS grew 25.0% and free cash flow fell 27.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.15
0.04
−3.36%
Follow RNXT
RenovoRx, Inc. (RNXT) P/E ratio
RenovoRx, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GUTS Fractyl Health, Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| RNXT RenovoRx, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)